Press "Enter" to skip to content

AbbVie’s Skyrizi drug to treat psoriasis wins U.S. approval

AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures.

Original source:

Also Read:   Bangladesh plans to ban e-cigarettes amid growing health concerns